The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
The proposed transaction will be effected as a share swap
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Both organisations enter into a long- term collaboration to expand patient access in India
Total transaction value of the divestment is Rs. 3,660 million
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
Eris Lifesciences has reported total income of Rs.1220.57 crores during the 12 months period ended March 31, 2021
Subscribe To Our Newsletter & Stay Updated
